Oleanolic acid inhibits hypertrophic scarring in the rabbit ear model

Clinical and Experimental Dermatology

Volumn 36, Issue 5, 2011, Pages 528-533

  Wei, Y J ^a,b   Yan, X Q ^c   Ma, L ^d   Wu, J G ^a   Zhang, H ^a   Qin, L P ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b FUJIAN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^c SECOND MILITARY MEDICAL UNIVERSITY   (China)

^d CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 1; COLLAGEN TYPE 3; CONTRACTUBEX; INTERSTITIAL COLLAGENASE; OLEANOLIC ACID; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; EAR; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX; FEMALE; FIBROBLAST; HISTOCHEMISTRY; HISTOLOGY; HYPERTROPHIC SCAR; MULTIPLE CYCLE TREATMENT; NONHUMAN; POSTOPERATIVE PERIOD; PRIORITY JOURNAL;

ANIMALS; CICATRIX, HYPERTROPHIC; COLLAGEN TYPE I; COLLAGEN TYPE III; DERMATOLOGIC AGENTS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; EAR, EXTERNAL; FEMALE; MATRIX METALLOPROTEINASE 1; OLEANOLIC ACID; RABBITS; SEVERITY OF ILLNESS INDEX; TRANSFORMING GROWTH FACTOR BETA1;

EID: 79959340053     PISSN: 03076938     EISSN: 13652230     Source Type: Journal    
DOI: 10.1111/j.1365-2230.2010.04012.x     Document Type: Article

References (16)

1. O'Leary R, Wood EJ, Guillou PJ. Pathological scarring: strategic interventions. Eur J Surg 2002; 168: 523-54.
2. Bock O, Schmid-Ott G, Malewski P, Mrowietz U. Quality of life of patients with keloid and hypertrophic scarring. Arch Dermatol Res 2006; 297: 433-8.
3. Mazharinia N, Aghaei S, Shayan Z. Dermatology Life Quality Index (DLQI) scores in burn victims after revival. J Burn Care Res 2007; 28: 312-17.
4. Reish RG, Eriksson E. Scar treatments: preclinical and clinical studies. J Am Coll Surg 2008; 206: 719-30.
5. Bloemen MC, van der Veer WM, Ulrich MM et al. Prevention and curative management of hypertrophic scar formation. Burns 2009; 35: 463-75.
6. Du J, Sun LN, Xing WW et al. Lipid-lowering effects of polydatin from Polygonum cuspidatum in hyperlipidemic hamsters. Phytomedicine 2009; 16: 652-8.
7. Wu JG, Wu JZ, Sun LN et al. Ameliorative effects of arctiin from Arctium lappa on experimental glomerulonephritis in rats. Phytomedicine 2009; 16: 1033-41.
8. Xing WW, Wu JZ, Jia M et al. Effects of polydatin from Polygonum cuspidatum on lipid profile in hyperlipidemic rabbits. Biomed Pharmacother 2009; 63: 457-62.
9. Kryger ZB, Sisco M, Roy NK et al. Temporal expression of the transforming growth factor-beta pathway in the rabbit ear model of wound healing and scarring. J Am Coll Surg 2007; 205: 78-88.
10. Beldon P. Abnormal scar formation in wound healing. Nurs Times 2000; 96: 44-5.
11. Clark JA, Cheng JC, Leung KS. Mechanical properties of normal skin and hypertrophic scar. Burns 1996; 22: 443-6.
12. Schaffer M, Becker HD. Immune regulation of wound healing. Chirurg 1999; 70: 897-908.
13. Hayakawa T, Hashimoto Y, Myokei Y et al. Changes in type of collagen during the development of human post-burn hypertrophic scars. Clin Chim Acta 1979; 93: 119-25.
14. Dasu MR, Hawkins HK, Barrow RE et al. Gene expression profiles from hypertrophic scar fibroblasts before and after IL-6 stimulation. J Pathol 2004; 202: 476-85.
15. Schmid P, Itin P, Cherry G et al. Enhanced expression of transforming growth factor-beta type I and type II receptors in wound granulation tissue and hypertrophic scar. Am J Pathol 1998; 152: 485-93.
16. Tuan TL, Nichter LS. The molecular basis of keloid and hypertrophic scar formation. Mol Med Today 1998; 4: 19-24.